Edwards Lifesciences Corporation Stock
Equities
EW
US28176E1082
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 83.08 USD | -1.38% |
|
-3.61% | +12.22% |
| Capitalization | 48.21B 41.07B 38.37B 36.1B 66.46B 4,367B 72.6B 448B 174B 2,058B 181B 177B 7,510B | P/E ratio 2025 * |
36.6x | P/E ratio 2026 * | 30.9x |
|---|---|---|---|---|---|
| Enterprise value | 44.92B 38.27B 35.75B 33.63B 61.92B 4,069B 67.65B 417B 162B 1,918B 169B 165B 6,997B | EV / Sales 2025 * |
7.45x | EV / Sales 2026 * | 6.61x |
| Free-Float |
89.32% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: Edwards Lifesciences Corporation
| 1 day | -1.38% | ||
| 1 week | -3.61% | ||
| Current month | -4.14% | ||
| 1 month | -3.73% | ||
| 3 months | +7.10% | ||
| 6 months | +10.55% | ||
| Current year | +12.22% |
| 1 week | 83.03 |  | 85.18 |
| 1 month | 83.03 | | 87.89 |
| Current year | 65.94 | | 87.89 |
| 1 year | 65.94 | | 87.89 |
| 3 years | 58.93 | | 96.12 |
| 5 years | 58.93 | | 131.73 |
| 10 years | 24.07 | | 131.73 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 57 | 2023-05-10 | |
Scott Ullem
DFI | Director of Finance/CFO | 58 | 2013-12-31 |
Todd Brinton
CTO | Chief Tech/Sci/R&D Officer | - | 2019-01-31 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 68 | 2024-05-06 | |
Kieran Gallahue
BRD | Director/Board Member | 61 | 2015-02-09 |
| Director/Board Member | 57 | 2023-05-10 |
| Name | Weight | AuM | Varia. Jan 1. | Investor |
|---|---|---|---|---|
 | 2.46% | 51 M€ | -2.77% | - |
| 2.34% | 26 M€ | +11.49% | - |
| 1.17% | 27 M€ | +1.08% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -1.38% | -3.61% | +13.31% | +9.58% | 48.21B | |
| -1.14% | -0.09% | +8.61% | +0.89% | 215B | |
| -0.92% | -5.74% | +0.51% | +93.24% | 192B | |
| -2.60% | +0.04% | -3.64% | -17.47% | 160B | |
| +0.90% | -5.07% | +2.74% | +96.23% | 137B | |
| +0.98% | +1.33% | -17.59% | -14.19% | 57.67B | |
| -2.23% | -3.99% | +0.49% | -9.77% | 39.54B | |
| -2.43% | -1.76% | +3.53% | - | 38.25B | |
| -0.05% | -1.67% | +5.76% | +14.22% | 36.77B | |
| +2.07% | -1.27% | -22.90% | -35.29% | 34.25B | |
| Average | -0.68% | -2.07% | -0.92% | +15.27% | 95.91B | |
| Weighted average by Cap. | -0.87% | -2.29% | +0.99% | +29.43% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 6.03B 5.14B 4.8B 4.52B 8.31B 546B 9.08B 56.02B 21.73B 257B 22.63B 22.15B 939B | 6.61B 5.64B 5.26B 4.95B 9.12B 599B 9.96B 61.44B 23.83B 282B 24.82B 24.3B 1,030B |
| Net income | 1.34B 1.14B 1.07B 1B 1.85B 121B 2.02B 12.45B 4.83B 57.22B 5.03B 4.92B 209B | 1.58B 1.34B 1.25B 1.18B 2.17B 143B 2.37B 14.64B 5.68B 67.27B 5.91B 5.79B 245B |
| Net Debt | -3.29B -2.8B -2.62B -2.46B -4.54B -298B -4.96B -30.56B -11.85B -140B -12.35B -12.09B -513B | -4.45B -3.79B -3.54B -3.33B -6.14B -403B -6.71B -41.37B -16.05B -190B -16.71B -16.36B -694B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-12-12 | 83.08 $ | -1.38% | 2,855,746 |
| 25-12-11 | 84.24 $ | +0.38% | 2,104,149 |
| 25-12-10 | 83.92 $ | +0.77% | 2,898,619 |
| 25-12-09 | 83.28 $ | -1.23% | 2,412,585 |
| 25-12-08 | 84.32 $ | -2.17% | 3,579,252 |
Delayed Quote Nyse, December 12, 2025 at 04:00 pm EST
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- EW Stock
Select your edition
All financial news and data tailored to specific country editions
